ASX:CSL
ASX:CSLBiotechs

CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England

CSL (ASX:CSL) saw its stock price rise by 3% over the last month, amid important developments and a fluctuating market environment. CSL Vifor's notable progress with the National Institute for Health and Care Excellence recommending sparsentan for primary IgA nephropathy treatment may have provided positive momentum. This significant medical endorsement, alongside CSL's continued engagement with shareholders through meetings, could have added weight to its share performance. Meanwhile,...
ASX:CQR
ASX:CQRRetail REITs

Exploring 3 Undervalued Small Caps In Global With Insider Action

As global markets react positively to the recent U.S.-China tariff suspension, with major indices like the Nasdaq Composite and S&P 500 showing significant gains, small-cap stocks have also benefited from this improved sentiment. In this environment of easing trade tensions and cooling inflation, identifying promising small-cap stocks involves looking for those with strong fundamentals and potential insider action that may signal confidence in their future growth.
ASX:NXL
ASX:NXLSoftware

ASX Penny Stocks With Market Caps Under A$900M

As Australian markets anticipate a modest 0.17% gain, investors are keeping a close eye on global developments and local economic indicators, such as the RBA's recent decisions and their implications for trade with China. In this context, penny stocks—though an older term—remain relevant as they offer potential growth opportunities in smaller or newer companies. With strong financial foundations, these stocks can present surprising value and stability; we'll explore several that stand out for...